RxDoctor Payments Data

Brittany Bowman

Optometrist · South Burlington, VTNPI 1891427258

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Biotissue Holdings Inc. at 26.1% of the total.

$689in general payments, 2019–2025

Across 10 payments — averaging $68.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$180
  • AbbVie$155
  • Bausch & Lomb Americas Inc.$153
  • Glaukos Corporation$141
  • Alcon$36
  • Sun Pharmaceutical Industries Inc.$25

What the payments were for

  • Food & beverage$689100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$689 in reported general payments places this provider in the 75th percentile of 80 optometrist providers in Vermont.

See all optometrist providers in Vermont

Medicare billing

Part B allowed, 2024
$307,928
Medicare patients
1,099
Services billed
3,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost131$74,979
RestasisCyclosporine53$65,124
Latanoprost1,032$18,319
Cyclosporine22$15,506
RocklatanNetarsudil Mesylat/Latanoprost31$14,198
RhopressaNetarsudil Mesylate27$12,831
SimbrinzaBrinzolamide/Brimonidine Tart47$12,478
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$12,060
Travoprost66$11,859
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat557$11,587
Brimonidine Tartrate215$8,367
Brinzolamide38$7,840
Timolol Maleate418$6,821
IyuzehLatanoprost/Pf13$5,791
Timolol MaleateTimolol Maleate/Pf16$5,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$155$140,104184 claims
AlconSimbrinza$36$12,47847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 80 optometrist providers in Vermont.

Other optometrist in South Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →